---
layout: default
title: Nitrogen
parent: 僅模型預測 (L5)
nav_order: 335
evidence_level: L5
indication_count: 10
---

# Nitrogen
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Nitrogen: From Undocumented Original Indication to 16q24.1 Microdeletion Syndrome

## One-Sentence Summary

Nitrogen (DrugBank DB09152) is a medical/industrial gas for which this evidence pack records no original indication and no mechanism-of-action data. The TxGNN model's top-ranked prediction points to **16q24.1 microdeletion syndrome**, an extremely rare chromosomal disorder, but this association is supported by **0 clinical trials** and **0 publications** — it is model output only, and the model's own rationale flags it as a likely artifact of sparse graph connectivity around rare-disease nodes rather than a real pharmacological signal.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not documented (no approved indication or SAHPRA license on file for Nitrogen) |
| Predicted New Indication | 16q24.1 microdeletion syndrome |
| TxGNN Prediction Score | 99.73% |
| Evidence Level | L5 (model prediction only) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Nitrogen is not currently available, and no original therapeutic indications are recorded in this dataset. Nitrogen is generally known as a medical/industrial gas (e.g., inert atmosphere for other therapeutic gas mixtures, cryotherapy carrier, respiratory diluent), but no specific approved indication is documented here.

The top-ranked predicted association carries no supporting clinical trial or literature evidence. Critically, the model's own repurposing rationale for this candidate states that the high TxGNN score "likely reflects a bias from sparse connectivity around this rare-disease node in the knowledge graph, rather than a genuine pharmacological signal" — there is no known or plausible mechanistic link between an inert gas and this rare chromosomal microdeletion syndrome.

This pattern is consistent across all 10 ranked predictions for Nitrogen: none progress beyond decision stage S0, all are scored Evidence Level L5, and where literature was retrieved (ranks 5, 6, 10), review shows it consists of keyword-coincidence hits (e.g., "nitrogen" appearing in urinary/blood nitrogen lab values, nitrogen mustard chemotherapy, or nitrogenous bisphosphonates) rather than studies evaluating Nitrogen gas itself as a therapeutic intervention. No candidate in this evidence pack currently constitutes a credible repurposing signal.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for the top-ranked indication (16q24.1 microdeletion syndrome).

---

## Literature Evidence

Currently no related literature available for the top-ranked indication (16q24.1 microdeletion syndrome).

---

## South Africa Market Information

Nitrogen has **0 SAHPRA registrations** and is currently **not marketed** in South Africa. No product-level registration, dosage form, or approved-indication data is available in this evidence pack.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The top-ranked prediction (16q24.1 microdeletion syndrome) has no clinical trial or literature support, and the model itself flags the score as a probable knowledge-graph artifact rather than a real signal. Combined with the absence of mechanism-of-action data, an undocumented original indication, and zero SAHPRA registrations, there is currently no basis to advance this candidate.

**To proceed, the following is needed:**
- TFDA/SAHPRA-approved Professional Information (PI), including warnings and contraindications — currently a **Blocking** data gap preventing any S1 safety review
- Verified mechanism-of-action (MOA) data for Nitrogen
- Independent pharmacological or expert review of whether any plausible mechanistic rationale exists linking Nitrogen to 16q24.1 microdeletion syndrome, given the model's own flag of likely graph-sparsity bias
- Re-screening of the remaining 9 ranked candidates for this drug, none of which currently clear L5/S0/Hold status
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

